CD19 and acute lymphoblastic leukemia: We combined the CD22 CAR-T incorporating of HIB22 scFv with CD19 CAR-T, which were derived from an HI19a hybridoma and were reported with great clinical efficacy [25], as salvage therapy for the treatment of 4 R/R B-ALL patients.